Screener
Tango Therapeutics TNGX Shares (Diluted)
Discontinued — last reported Q1 '26
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Provision for income taxes | (1) | (34) |
| Net loss | $(45,514) | $(39,876) |
| Net loss per common share – basic and diluted | $(0.32) | $(0.36) |
| Weighted average number of common shares outstanding – basic and diluted | 143,576,292 | 110,301,256 |
| Net loss | $(45,514) | $(39,876) |
| Other comprehensive income (loss): | ||
| Unrealized (loss) gain on marketable securities | (339) | (142) |
| Comprehensive loss | $(45,853) | $(40,018) |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's shares (diluted)?
- Tango Therapeutics (TNGX) reported shares (diluted) of 143.6M in Q1 2026.
- How has Tango Therapeutics's shares (diluted) changed year-over-year?
- Tango Therapeutics's shares (diluted) increased by 30.2% year-over-year, from 110.3M to 143.6M.
- What is the long-term trend for Tango Therapeutics's shares (diluted)?
- Over 4 years (2021 to 2025), Tango Therapeutics's shares (diluted) has grown at a 19.6% compound annual growth rate (CAGR), from 222.4M to 454.8M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Tango Therapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude